Please try another search
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer’s disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson’s disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.
Name | Age | Since | Title |
---|---|---|---|
Maykin Ho | 70 | 2021 | Independent Director |
Matthew K. Fust | 58 | 2020 | Independent Director |
Kristina M. Burow | 50 | 2020 | Independent Director |
Gaurav Singal | - | - | Member of Technology Advisory Board |
Patrick Sullivan | - | - | Member of Scientific Advisory Board |
Diego A. Pizzagalli | - | - | Member of Technology Advisory Board |
John D. Murray | - | - | Member of Technology Advisory Board |
Sandeep Robert Datta | - | - | Member of Scientific Advisory Board |
Andrew Trister | - | - | Member of Technology Advisory Board |
Mark Daly | - | - | Member of Scientific Advisory Board |
Richard Huganir | - | - | Member of Scientific Advisory Board |
Iain McFadyen | - | - | Member of Technology Advisory Board |
Edward Roberts | - | - | Member of Scientific Advisory Board |
Benjamin Neale | - | - | Member of Scientific Advisory Board |
John Krystal | - | - | Member of Scientific Advisory Board |
Alex Wiltschko | - | 2023 | Member of Technology Advisory Board |
Hugh Rosen | 65 | - | Member of Scientific Advisory Board |
Beth Stevens | - | - | Member of Scientific Advisory Board |
Alan Anticevic | - | - | Member of Technology Advisory Board |
Paul L. Berns | 57 | 2020 | Co-Founder & Executive Chairman |
Bernardo L. Sabatini | - | - | Member of Scientific Advisory Board |
David A. Piacquad | 67 | 2023 | Independent Director |
Morgan H. Sheng | 66 | - | Member of Scientific Advisory Board |
Alaa Halawa | 41 | 2022 | Independent Director |
Edward M. Scolnick | 83 | - | Member of Scientific Advisory Board |
Henry O. Gosebruch | 51 | 2023 | President, CEO & Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review